Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Barclays PLC

Barclays PLC increased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 94.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 85,395 shares of the company’s stock after buying an additional 41,394 shares during the quarter. Barclays PLC owned about 0.13% of Vera Therapeutics worth $3,774,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of VERA. Bank of New York Mellon Corp increased its stake in shares of Vera Therapeutics by 6.3% in the second quarter. Bank of New York Mellon Corp now owns 165,322 shares of the company’s stock worth $5,981,000 after acquiring an additional 9,854 shares during the period. Legato Capital Management LLC acquired a new position in shares of Vera Therapeutics in the 2nd quarter valued at about $273,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Vera Therapeutics by 30.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,527 shares of the company’s stock worth $272,000 after buying an additional 1,737 shares during the last quarter. TD Asset Management Inc grew its holdings in Vera Therapeutics by 18.4% during the second quarter. TD Asset Management Inc now owns 154,338 shares of the company’s stock worth $5,584,000 after acquiring an additional 24,000 shares during the period. Finally, Victory Capital Management Inc. raised its position in Vera Therapeutics by 202.4% during the second quarter. Victory Capital Management Inc. now owns 33,707 shares of the company’s stock valued at $1,220,000 after acquiring an additional 22,560 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on VERA shares. Wells Fargo & Company assumed coverage on Vera Therapeutics in a research report on Thursday, November 21st. They issued an “overweight” rating and a $70.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 price target on shares of Vera Therapeutics in a research report on Tuesday, October 1st. Wedbush upped their price objective on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Guggenheim raised their target price on Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research report on Monday, October 28th. Finally, JPMorgan Chase & Co. upped their price target on Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $59.22.

Vera Therapeutics Trading Up 1.3 %

VERA stock opened at $42.60 on Monday. Vera Therapeutics, Inc. has a 12-month low of $14.20 and a 12-month high of $51.61. The business’s 50-day moving average is $45.27 and its 200 day moving average is $40.50. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a market cap of $2.70 billion, a price-to-earnings ratio of -16.32 and a beta of 1.08.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). On average, sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total transaction of $753,725.00. Following the transaction, the chief executive officer now directly owns 85,942 shares in the company, valued at approximately $3,701,521.94. The trade was a 16.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Beth C. Seidenberg sold 15,000 shares of the stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $48.03, for a total transaction of $720,450.00. Following the completion of the sale, the director now owns 131,553 shares of the company’s stock, valued at approximately $6,318,490.59. The trade was a 10.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 108,125 shares of company stock valued at $4,740,588 over the last 90 days. 21.70% of the stock is currently owned by corporate insiders.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.